It's time pharmaceutical companies rethink the incentives, business models and partnerships that make medicines affordable, accessible and commercially sustainable in the markets with the greatest need.
Over more than two decades, I have met countless pharmaceutical chief executives and shareholders to make the case for equitable access to medicines. Rarely have we disagreed.
The industry’s desire to bring life-saving treatments to the millions who need them is real. What has been missing is a system of incentives strong enough to turn that sentiment into access at scale.
Pharmaceutical companies are central to global health. They not only drive biomedical innovation but they also decide where medicines are registered, how they are priced and ultimately, who can access them.
Today, that responsibility is becoming acute because scientific innovation is advancing faster than the systems needed to deliver it equitably.
Change is possible. My organization has just published the 10th edition of the Access to Medicine Index, a 20-year endeavour which tracks how the world’s leading drugmakers are making essential medicines and other health products available and affordable in low- and middle-income countries.
What the data tells us
Encouragingly, the index finds that companies increasingly treat access as a strategic issue, rather than a peripheral corporate responsibility. More businesses are embedding it in operations and giving it greater attention in the boardroom.
However, progress remains slow and uneven. Although a wider range of medicines is reaching low- and middle-income countries, gaps persist and geopolitical headwinds threaten to derail hard-won gains.
Rising economic nationalism is pushing companies to prioritize domestic markets, while drastic cuts in international aid budgets are jeopardizing funding for the health infrastructure needed to distribute life-saving therapies and vaccines.
This is a critical moment. In the face of these challenges, leaders of the world’s major pharmaceutical companies need to redouble their commitment to extend medical innovation to those who need it most.
The opportunity with an access plan
The industry has a range of promising new medicines with the potential to change millions of lives worldwide, including better and more convenient products for obesity, HIV, hepatitis B, sickle cell disease, group B streptococcus and drug-resistant malaria. And there are signs suggesting companies are thinking about access earlier in the drug development process.
Some 69% of late-stage pipeline candidates are now covered by an access plan, more than triple the proportion in 2018. Yet the scope of these plans varies considerably when it comes to commitments on affordability, reliable supply and reaching patients in the poorest countries.
The shortcomings are especially apparent in non-communicable diseases, which account for a growing share of the disease burden in low- and middle-income countries. Access initiatives for these conditions focus primarily on upper-middle-income countries, often overlooking poorer populations.
Cancer, diabetes and obesity expose the gaps in equitable access
Cancer illustrates both the progress and the limitations. Today, 65% of oncology pipeline candidates have an access plan, up from just 5% in 2018. Companies are clearly thinking earlier about making innovative treatments available beyond wealthy markets. Yet the geographical reach of these initiatives remains narrow, leaving too many patients without access to potentially life-saving therapies.
Similar problems are apparent in diabetes and obesity. GLP-1 medicines, such as Ozempic, are transforming the treatment of conditions in wealthier countries and new formulations, including oral alternatives to injections, which could make them easier to deliver in resource-constrained settings.
Since both diabetes and obesity are increasingly prevalent in low- and middle-income countries, the potential benefits are sizable. Unfortunately, access plans remain weak for non-communicable diseases, particularly around equitable pricing and product registration in lower-income markets.
This is short-sighted from a business and public health perspective. Around 80% of the world’s population lives in low- and middle-income countries and these markets will become increasingly important. They may offer lower margins but that is precisely why companies need to develop new ways to serve them profitably.
Some are already developing with novel approaches. Alongside their traditional commercial operations, they have established distinct businesses that offer portfolios of medicines at lower prices, effectively creating a company within a company.
The challenge is to make such ideas normal business practice rather than the exception and to do it where demand is growing fastest.
New business models can make equitable access commercially viable
In emerging and developing markets, demand is rising quickly for non-communicable diseases such as cardiovascular disease, diabetes, and cancer, where companies have the most to gain from expanding patient reach and growing their business.
Doing so requires rewarding companies for reaching patients who would otherwise be excluded. This could include a wide range of measures, from coordinated procurement and advance purchase agreements that give manufacturers predictable volumes in low- and middle-income countries to management incentive schemes that treat access as a material performance measure.
Our Index, which has publicly benchmarked companies since 2008, shows how a non-financial incentive system can also help shift corporate behaviour. Transparency, comparison and accountability can help make access a boardroom priority.
Shareholders too, are also increasingly recognizing the importance of pharmaceutical companies that integrate social and environmental benefits while still delivering returns.
I have learned over the years that there is no single business model that can close the access gap. Progress depends on combining different approaches: conventional commercial distribution, lower-margin and non-commercial models, voluntary licensing and technology transfer. What works for one medicine or market may not work for another.
In the years ahead, the pharmaceutical industry will undoubtedly develop yet more transformative medicines. The big test will be whether it can build the business models and partnerships needed to make the promise of scientific innovation a reality for all.





